Spadoni G L, Tally M, Florell K, Enberg G, Hall K
Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden.
J Endocrinol Invest. 1990 Feb;13(2):97-102. doi: 10.1007/BF03349516.
A homologous radioreceptor assay (RRA) has been developed for Insulin-like Growth Factor II (IGF II) using the human erythroleukemia cell line K562. These cells have binding sites for insulin and IGF-II but not for Insulin-like Growth Factor I (IGF I). All samples were dissociated and separated from binding proteins by gel filtration at acidic pH. In healthy adults the mean serum level of radioreceptor assayable IGF II (RRA-IGF II) and 95% confidence limits were 965 ng/ml and 717-1299 ng/ml, respectively. The mean level in GH deficient patients was significantly lower (p less than 0.001) compared with healthy subjects whereas no change was found in patients with acromegaly and uremia. Slightly lowered levels of RRA-IGF II were found in one patient with a tumor induced hypoglycemia.
已利用人红白血病细胞系K562开发出一种用于胰岛素样生长因子II（IGF II）的同源放射受体分析（RRA）方法。这些细胞具有胰岛素和IGF-II的结合位点，但不具有胰岛素样生长因子I（IGF I）的结合位点。所有样品在酸性pH条件下通过凝胶过滤与结合蛋白解离并分离。在健康成年人中，可通过放射受体分析检测到的IGF II（RRA-IGF II）的平均血清水平及95%置信区间分别为965 ng/ml和717 - 1299 ng/ml。与健康受试者相比，生长激素缺乏患者的平均水平显著降低（p < 0.001），而肢端肥大症和尿毒症患者未发现变化。在一名肿瘤诱导性低血糖患者中发现RRA-IGF II水平略有降低。
